Clinical trials are extremely expensive, yet many rely on clinician-based assessments that are inconsistent at best. As challenging as it is to bring a new drug to market, one thing should be fundamental: You can’t afford bad incoming data.
Through the dynamic real-time review of incoming subject data, PES moves forward any data problems that typically come at the end of a trial – this has many benefits: